title: Inhibition of MAP kinase kinase (MEK) results in an anti-inflammatory response in vivo.
abstract: The MAP kinase pathway has been well-characterized as a cascade of sequential protein phosphorylation events leading to the upregulation of a variety of genes in response to growth factors and mitogens. We are interested in the role of these kinases in inflammation and have thus examined their activity in vivo using TPA-induced ear edema in the mouse as a model of inflammation. We show that the activities of both ERK-1 and ERK-2 are upregulated in this model in response to TPA. Increased levels of ERK phosphorylation are measurable as early as 15 min poststimulation and reach a level 8-fold over controls at 4 h. In contrast, minimal activation of JNK or p38 is observed. Topical treatment of ears with the MEK inhibitor, U0126, prevents ERK phosphorylation and ear swelling in a dose-dependent manner in this model. These results suggest that the MEK/ERK pathway is important during an inflammatory response in vivo.
authors.affiliation: DuPont Pharmaceuticals Company, Inflammatory Diseases Research, Wilmington, Delaware 19880-0400, USA.
authors.forename: B D
authors.initials: BD
authors.lastname: Jaffee
authors.forename: E J
authors.initials: EJ
authors.lastname: Manos
authors.forename: R J
authors.initials: RJ
authors.lastname: Collins
authors.forename: P M
authors.initials: PM
authors.lastname: Czerniak
authors.forename: M F
authors.initials: MF
authors.lastname: Favata
authors.forename: R L
authors.initials: RL
authors.lastname: Magolda
authors.forename: P A
authors.initials: PA
authors.lastname: Scherle
authors.forename: J M
authors.initials: JM
authors.lastname: Trzaskos
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D002070:Butadienes / Q000494:pharmacology / Q000627:therapeutic use; D004487:Edema / Q000517:prevention & control; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D048031:JNK Mitogen-Activated Protein Kinases; D048369:MAP Kinase Kinase 1; D008297:Male; D051379:Mice; D048052:Mitogen-Activated Protein Kinase 3; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors*; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D009570:Nitriles / Q000494:pharmacology / Q000627:therapeutic use; D010766:Phosphorylation; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D000893:Anti-Inflammatory Agents; D002070:Butadienes; D004791:Enzyme Inhibitors; D009570:Nitriles; C113580:U 0126; D017346:Protein Serine-Threonine Kinases; D048031:JNK Mitogen-Activated Protein Kinases; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases; D048369:MAP Kinase Kinase 1; C482127:Map2k1 protein, mouse; D020929:Mitogen-Activated Protein Kinase Kinases